EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

CSPHF fair value: what the stock is really worth

We calculate from audited financials what CSPHF is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN KYG2588M1006

C CSPHF logo Thin data Sep 13, 2026

CSPHF

CSPHF · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $0.6300 · Overvalued (−31%)
!Quality 26/100
!Weak Growth (revenue 5y −24.0 %/yr)
!Loss-making · -162.1% net margin (TTM)
!Low debt · negative free cash flow
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$2.15 $0.1140 Fair Value $0.6300 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range $0.1140 – $2.15 · fair‑value band $0.4100 – $0.7800 · the $0.9110 price screens above the $0.6300 fair value. Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally.

Show more

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.

Stock analysis

CSPHF (CSPHF) currently trades at $0.9110, while our model-based Fair Value estimate is $0.6300, implying the stock looks roughly 44.6% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.4100 (bear) to $0.7800 (bull), the price of $0.9110 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

CSPHF reported revenue of 263M CNY in FY2025 versus 244M CNY in FY2021, a compound +1.9%/yr. Reported net income was −426M CNY in FY2025.

Key figures

Market cap $1.3B · P/S ratio 3.53 · EPS (TTM) $−0.0500 · Net margin −162% · Return on equity −89.1% · Return on assets (EBIT) −41.7% · Operating margin −63.0% · Revenue (TTM) $270M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 10% below its 52-week high and 76% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −31%, CSPHF screens richer than that median.

Fair Value models

Bear $0.4100 Fair Value $0.6300 Bull $0.7800
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.1900 $0.2600 $0.3900 53
All 1 models by family
Asset-Based
NCAV (Graham) $0.1900 $0.2600 $0.3900 53

Open the full fair value analysis →

Notify me when CSPHF reaches fair value

Put CSPHF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 26/100

Of which business quality 29 · Market factors (momentum, volatility) 51

Profitability 2
Margins and returns on capital today
Quality Growth 0
Are margins and returns improving?
Cashflow 30
Earnings quality: real cash, not paper profit
Fin. Strength 59
Balance sheet, leverage, solvency risk
Investment 81
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 47
Price trend over the last 3–12 months (market factor)
52W Momentum 60
Distance to the 52-week high (market factor)
Net Issuance 11
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−35.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.0%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+49.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−105.1% (2020) → −160.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CSPHF screens 45% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare CSPHF with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $515.44 $566.98 +10%
Regeneron Pharmaceuticals, Inc REGN $781.49 $1,241 +59%
argenx SE ARGX €853.80 €752.12 −12%
BeOne Medicines AG 688235 ¥247.30 ¥124.62 −50%
Samsung Biologics Co 207940 1,415,000 KRW 1,556,500 KRW +10%
Alnylam Pharmaceuticals, Inc ALNY $248.68 $211.88 −15%
Royalty Pharma plc RPRX $58.61 $24.22 −59%
Celltrion, Inc 068270 178,200 KRW 74,519 KRW −58%
BioNTech SE BNTX $96.73 $63.31 −35%
Incyte Corporation INCY $121.47 $204.93 +69%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CSPHF · Fair Value
$0.6300 −45%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "CSPHF Fair Value". https://www.fairvalue-calculator.com/stock/CSPHF

Frequently asked questions

Is CSPHF overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $0.6300 versus a price of $0.9110, about −31% upside (overvalued).
What is the fair value of CSPHF?
Our model-based fair value for CSPHF is $0.6300 (as of Sep 13, 2026), built from audited fundamentals. The current price: $0.9110.
What is the quality score of CSPHF?
CSPHF has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CSPHF?
Our model-based price target is the fair value of $0.6300 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario $0.4100, optimistic scenario $0.7800. It is a calculation from audited fundamentals, not an analyst target.
What is the CSPHF stock forecast for 2026?
Our models put fair value at $0.6300, about −31% upside versus a price of $0.9110 (overvalued). Cautious scenario $0.4100, optimistic scenario $0.7800. The calculation is refreshed regularly with new filings.
What is the revenue of CSPHF?
CSPHF reported trailing-twelve-month revenue of about $270M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of CSPHF?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CSPHF it is $0.6300 per share (as of Sep 13, 2026), against a price of $0.9110. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is CSPHF stock overvalued or undervalued in 2026?
As of Sep 13, 2026, CSPHF trades above its calculated fair value: price $0.9110, fair value $0.6300, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CSPHF?
No. The price is what the market pays today ($0.9110); the fair value is what the company's own numbers justify ($0.6300). For CSPHF the two are $0.2810 per share apart. That gap is exactly why we show both numbers side by side.
How much is CSPHF worth?
The market values CSPHF at about $1.3B (market capitalisation, as of Sep 13, 2026). Per share that is $0.9110; our models calculate a fair value of $0.6300 per share.
What do the bullish and bearish scenarios say about CSPHF?
Our models span a range for CSPHF: cautious scenario $0.4100, base $0.6300, optimistic $0.7800 per share (as of Sep 13, 2026, price $0.9110). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is CSPHF from its 52-week high?
CSPHF trades at $0.9110, about 10% below its 52-week high of $1.01 and 76% above the low of $0.5180 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6300 is for.
Which stocks are comparable to CSPHF?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CSPHF stock attractive at the current price?
The data as of Sep 13, 2026: price $0.9110, calculated fair value $0.6300 (−31%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CSPHF calculated?
We run CSPHF through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. CSPHF itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with CSPHF right now?
The price sits above even our optimistic bull case ($0.7800). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.4100 to $0.7800) leaves room in how you read the outcome.

Key figures of CSPHF

How large is the market capitalisation of CSPHF?
The market capitalisation of CSPHF is $1.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CSPHF?
The price-to-sales ratio of CSPHF is 3.53 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CSPHF?
Earnings per share at CSPHF are $−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of CSPHF?
The net margin of CSPHF is −162% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CSPHF?
The return on equity (ROE) of CSPHF is −89.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CSPHF?
On an EBIT basis the return on assets of CSPHF is −41.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CSPHF?
The operating margin of CSPHF is −63.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CSPHF?
Revenue at CSPHF is growing +43.8% versus a year earlier (3y avg −18.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CSPHF generate?
The free cash flow of CSPHF is −$328M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CSPHF hold?
CSPHF holds more cash than debt, $405M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.